Status:
COMPLETED
Stability of Tacrolimus, Cyclosporine A, Everolimus and Sirolimus in Whole Blood Patient Samples
Lead Sponsor:
Thermo Fisher Scientific Oy
Collaborating Sponsors:
ICON plc
Conditions:
Transplantation Drugs Stability
Eligibility:
All Genders
18+ years
Brief Summary
This is a prospective, observational evaluation study to assess the stability of the analytes tacrolimus, cyclosporine A, everolimus and sirolimus measured with Cascadion™ SM Immunosuppressants Panel....
Eligibility Criteria
Inclusion
- Age ≥18 years
- Ability to sign informed consent form
- At least one of the following
- Kidney, liver or heart transplant patient using tacrolimus or cyclosporine A
- Kidney or liver transplant patient using everolimus
- Kidney transplant patient using sirolimus
Exclusion
- Inability to provide informed consent
- Pregnancy or breastfeeding
- Likely to believe that the sample collection procedure will pose an unusually high risk for subject's physical or mental health or their comfort
Key Trial Info
Start Date :
February 7 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 26 2022
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT05274308
Start Date
February 7 2022
End Date
July 26 2022
Last Update
October 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AOU Città della Salute e della Scienza di Torino/S.C Biochimica Clinica
Turin, Italy, 10126